0001087294 2026-05-14 2026-05-14 0001087294 1 2026-05-14 2026-05-14 iso4217:USD pure SC 14A PREM14A EX-FILING FEES 0001087294 CUMBERLAND PHARMACEUTICALS INC N/A true false 100000000.00 0.0001381 13810.00 100000000.00 13810.00 0.00 0.00 13810.00 Calculated for the purpose of determining the filing fee in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The proposed maximum aggregate value of the transaction represents the $100 million cash payment amount to be paid to Cumberland Pharmaceuticals Inc. (the "Company") in connection with the completion of the transactions contemplated by that certain Asset Purchase Agreement, dated as of April 22, 2026, by and among Nuvo Pharmaceuticals (Ireland) DAC, Apotex Inc., and the Company. In accordance with Section 14(g) of the Exchange Act and Rule 0-11 of the Exchange Act, the filing fee was determined by multiplying the proposed maximum aggregate value of the transaction by 0.00013810.